147 related articles for article (PubMed ID: 3470260)
1. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
Haglund C; Kuusela P; Jalanko H; Roberts PJ
Int J Cancer; 1987 Apr; 39(4):477-81. PubMed ID: 3470260
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
4. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
6. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
[TBL] [Abstract][Full Text] [Related]
7. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma.
Sakahara H; Endo K; Nakajima K; Nakashima T; Koizumi M; Ohta H; Hidaka A; Kohno S; Nakano Y; Naito A
Cancer; 1986 Apr; 57(7):1324-6. PubMed ID: 3456252
[TBL] [Abstract][Full Text] [Related]
8. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
9. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis.
Del Favero G; Fabris C; Plebani M; Panucci A; Piccoli A; Perobelli L; Pedrazzoli S; Baccaglini U; Burlina A; Naccarato R
Cancer; 1986 Apr; 57(8):1576-9. PubMed ID: 3456255
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of CA 19-9 radioimmunoassay].
Toya D; Takemori Y; Kidani H; Yoneshima M; Hattori N; Sawabu N
Gan To Kagaku Ryoho; 1984 Mar; 11(3):509-14. PubMed ID: 6584087
[TBL] [Abstract][Full Text] [Related]
12. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers.
Sawabu N; Toya D; Takemori Y; Hattori N; Fukui M
Int J Cancer; 1986 May; 37(5):693-6. PubMed ID: 3457770
[TBL] [Abstract][Full Text] [Related]
13. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9.
Haglund C; Lindgren J; Roberts PJ; Nordling S
Int J Cancer; 1986 Dec; 38(6):841-6. PubMed ID: 3466871
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
15. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
[TBL] [Abstract][Full Text] [Related]
16. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
18. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor.
Tatsuta M; Yamamura H; Iishi H; Ichii M; Noguchi S; Yamamoto R; Okuda S
Cancer; 1985 Dec; 56(11):2669-73. PubMed ID: 3863691
[TBL] [Abstract][Full Text] [Related]
19. [Is jaundice a cause of error in the interpretation of CA 19-9 blood levels?].
Nakad A; Colombel JF; Geubel AP; Cerulus G; Farchakh E; Degrez T; Janssen J; Cortot A; Paris JC; Dive C
Acta Gastroenterol Belg; 1989; 52(1-2):17-22. PubMed ID: 2618531
[TBL] [Abstract][Full Text] [Related]
20. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
Röthlin M; Metzger U; Joller H; Largiadèr F
Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
